Post hoc subgroup analysis and the truth of a clinical trial

被引:23
作者
Adams, KF [1 ]
机构
[1] Univ N Carolina, Chapel Hill, NC USA
关键词
D O I
10.1016/S0002-8703(98)70116-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:753 / 758
页数:6
相关论文
共 22 条
[1]  
[Anonymous], 1988, LANCET, V2, P349
[2]  
[Anonymous], 1990, Lancet, V336, P1
[3]  
Feldman A., 1997, Journal of the American College of Cardiology, V29, p64A
[4]   EFFECTS OF VESNARINONE ON MORBIDITY AND MORTALITY IN PATIENTS WITH HEART-FAILURE [J].
FELDMAN, AM ;
BRISTOW, MR ;
PARMLEY, WW ;
CARSON, PE ;
PEPINE, CJ ;
GILBERT, EM ;
STROBECK, JE ;
HENDRIX, GH ;
POWERS, ER ;
BAIN, RP ;
WHITE, BG .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :149-155
[5]   TESTING FOR QUALITATIVE INTERACTIONS BETWEEN TREATMENT EFFECTS AND PATIENT SUBSETS [J].
GAIL, M ;
SIMON, R .
BIOMETRICS, 1985, 41 (02) :361-372
[6]   APPROXIMATE MULTINORMAL PROBABILITIES APPLIED TO CORRELATED MULTIPLE END-POINTS IN CLINICAL-TRIALS [J].
JAMES, S .
STATISTICS IN MEDICINE, 1991, 10 (07) :1123-1135
[7]   Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy [J].
Kass, DA ;
VanAnden, E ;
Becker, LC ;
Kasper, EK ;
White, WB ;
Feldman, AM .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (06) :652-656
[8]   Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart [J].
Kitakaze, M ;
Minamino, T ;
Funaya, H ;
Node, K ;
Shinozaki, Y ;
Mori, H ;
Hori, M .
CIRCULATION, 1997, 95 (08) :2108-2114
[9]   CLINICAL JUDGMENT AND STATISTICS - LESSONS FROM A SIMULATED RANDOMIZED TRIAL IN CORONARY-ARTERY DISEASE [J].
LEE, KL ;
MCNEER, JF ;
STARMER, CF ;
HARRIS, PJ ;
ROSATI, RA .
CIRCULATION, 1980, 61 (03) :508-515
[10]   VESNARINONE, A NEW INOTROPIC AGENT, INHIBITS CYTOKINE PRODUCTION BY STIMULATED HUMAN BLOOD FROM PATIENTS WITH HEART-FAILURE [J].
MATSUMORI, A ;
SHIOI, T ;
YAMADA, T ;
MATSUI, S ;
SASAYAMA, S .
CIRCULATION, 1994, 89 (03) :955-958